Time to Think about HLA-Based Diagnostics in Lung Cancer?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37756560.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2152.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HLA evolutionary divergence reflects the ability to recognize diverse neoantigens as non-self, and as a biomarker is conceptually distinct from programmed cell death ligand 1 expression and tumor mutation burden. HLA-based assays to predict benefit from immunotherapy in lung cancer require prospective validation. See related article by Jiang et al., p. 4830.
Medical subject headings
- Lung Neoplasms